SCHEMBL17237434

SCHEMBL17237434

COc1ccc(C(=O)C=CNc2cccc(C=Cc3cc(OC)c(OC)c(OC)c3)c2)cc1N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TUBB1 Q9H4B7 2/20 0.55
▸ NPC1 O15118 2/20 0.55
▸ RAB9A P51151 2/20 0.55
▸ ABCB1 P08183 5/20 0.54
▸ TUBB4A P04350 1/20 0.52
▸ TUBB P07437 1/20 0.52
▸ TUBA3C P0DPH7 1/20 0.52
▸ TUBA1B P68363 1/20 0.52
▸ TUBA4A P68366 1/20 0.52
▸ TUBB4B P68371 1/20 0.52
▸ TUBB3 Q13509 1/20 0.52
▸ TUBB2A Q13885 1/20 0.52
▸ TUBB8 Q3ZCM7 1/20 0.52
▸ TUBA3E Q6PEY2 1/20 0.52
▸ TUBA1A Q71U36 1/20 0.52
▸ TUBA1C Q9BQE3 1/20 0.52
▸ TUBB6 Q9BUF5 1/20 0.52
▸ TUBB2B Q9BVA1 1/20 0.52
▸ CA1 P00915 1/20 0.52
▸ CA2 P00918 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17237433 1.00 TUBB1 (0.55) TUBB1NPC1RAB9AABCB1TUBB4A
SCHEMBL17244277 1.00 TUBB1 (0.55) TUBB1NPC1RAB9AABCB1TUBB4A
SCHEMBL17237431 1.00 TUBB1 (0.55) TUBB1NPC1RAB9AABCB1TUBB4A
SCHEMBL17244281 0.91 NPC1 (0.67) NPC1RAB9AABCB1ABCG2KDM4E
SCHEMBL17237362 0.91 NPC1 (0.67) NPC1RAB9AABCB1ABCG2KDM4E
SCHEMBL17237360 0.91 NPC1 (0.67) NPC1RAB9AABCB1ABCG2KDM4E
SCHEMBL17237358 0.91 NPC1 (0.67) NPC1RAB9AABCB1ABCG2KDM4E
SCHEMBL17244269 0.90 CA1 (0.66) NPC1RAB9AABCB1CA1CA2
SCHEMBL17237304 0.90 CA1 (0.66) NPC1RAB9AABCB1CA1CA2
SCHEMBL17237297 0.90 CA1 (0.66) NPC1RAB9AABCB1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2942345-B1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES FOR THE TREATMENT OF CANCER COUNCIL SCIENT IND RES (IN) 2018-03-28 — — EP claimed
EP-2942345-A1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES for the treatment of cancer Council of Scientific and Industrial Research (IN) 2015-11-11 — — EP claimed
EP-2942345-B1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES FOR THE TREATMENT OF CANCER COUNCIL SCIENT IND RES (IN) 2018-03-28 — — EP disclosed
US-9487482-B2 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-11-08 — — US disclosed
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2015-11-12 — — US disclosed
EP-2942345-A1 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES for the treatment of cancer Council of Scientific and Industrial Research (IN) 2015-11-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322009-A1 NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS MCL1, HCCS, CASP3 TUBB1 853/4885NPC1 1040/4885RAB9A 3123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback